{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "23458769",
  "DateCompleted": {
    "Year": "2013",
    "Month": "08",
    "Day": "19"
  },
  "DateRevised": {
    "Year": "2024",
    "Month": "01",
    "Day": "09"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1586/eri.13.12"
    ],
    "Journal": {
      "ISSN": "1744-8336",
      "JournalIssue": {
        "Volume": "11",
        "Issue": "3",
        "PubDate": {
          "Year": "2013",
          "Month": "Mar"
        }
      },
      "Title": "Expert review of anti-infective therapy",
      "ISOAbbreviation": "Expert Rev Anti Infect Ther"
    },
    "ArticleTitle": "Clinical relevance of the ESKAPE pathogens.",
    "Pagination": {
      "StartPage": "297",
      "EndPage": "308",
      "MedlinePgn": "297-308"
    },
    "Abstract": {
      "AbstractText": [
        "In recent years, the Infectious Diseases Society of America has highlighted a faction of antibiotic-resistant bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) - acronymically dubbed 'the ESKAPE pathogens' - capable of 'escaping' the biocidal action of antibiotics and mutually representing new paradigms in pathogenesis, transmission and resistance. This review aims to consolidate clinically relevant background information on the ESKAPE pathogens and provide a contemporary summary of bacterial resistance, alongside pertinent microbiological considerations necessary to face the mounting threat of antimicrobial resistance."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97\u00a0Lisburn Road, Belfast, BT9 7BL, UK."
          }
        ],
        "LastName": "Pendleton",
        "ForeName": "Jack N",
        "Initials": "JN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gorman",
        "ForeName": "Sean P",
        "Initials": "SP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gilmore",
        "ForeName": "Brendan F",
        "Initials": "BF"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Expert Rev Anti Infect Ther",
    "NlmUniqueID": "101181284",
    "ISSNLinking": "1478-7210"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [
        "drug therapy",
        "microbiology",
        "physiopathology",
        "transmission"
      ],
      "DescriptorName": "Bacterial Infections"
    },
    {
      "QualifierName": [
        "drug therapy",
        "microbiology",
        "physiopathology",
        "transmission"
      ],
      "DescriptorName": "Cross Infection"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Drug Resistance, Multiple, Bacterial"
    },
    {
      "QualifierName": [
        "classification",
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Gram-Negative Bacteria"
    },
    {
      "QualifierName": [
        "classification",
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Gram-Positive Cocci"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    }
  ]
}